Table 3. Antiviral Activity in Influenza Virus-Infected MDCKa Cells.
| antiviral activity (μM) |
|
||||||
|---|---|---|---|---|---|---|---|
| A/PR/8/34 |
A/HK/7/87 |
cytotoxicity (μM) |
|||||
| compd | EC50 (CPE)b | EC50 (MTS)b | EC50 (CPE)b | EC50 (MTS)b | EC99 (virus yield)c | CC50d | MCCe |
| 4 | >100 | >100 | 6.2 | 8.0 | 20 | 54 | 100 |
| 5 | >100 | >100 | >100 | >100 | ND | 39 | 100 |
| 6 | >100 | >100 | 6.0 | 2.7 | <0.4 | 49 | 100 |
| 7 | >100 | >100 | >100 | >100 | ND | 41 | 100 |
| 8 | ≤0.80 | <0.80 | >100 | >100 | ND | 46 | 100 |
| 9 | >100 | >100 | >100 | >100 | ND | 9.0 | 20 |
| 11 | 1.3 | <0.80 | >100 | >100 | >10 | 4.9 | 15 |
| 12 | >100 | >100 | >100 | >100 | <0.08 | 1.9 | 4 |
| 13 | >100 | >100 | >100 | >100 | >10 | 9.4 | 20 |
| 14 | >100 | >100 | >100 | >100 | 4.6 | 1.9 | 4 |
| 18 | 1.8 | 3.0 | >100 | >100 | >50 | 49 | 100 |
| 19 | >100 | >100 | >100 | >100 | >10 | 15 | ≥4 |
| amantadine | 30 | 34 | 1.4 | 1.4 | 1.1 | >500 | ≥500 |
| rimantadine | 7.6 | 5.1 | 0.81 | 0.15 | >4 | 230 | 500 |
MDCK: Madin–Darby canine kidney cells; virus strains: A/PR/8/34 (A/H1N1) and A/HK/7/87 (A/H3N2).
50% effective concentration, or compound concentration producing 50% inhibition of virus replication, as determined by microscopic scoring of the CPE at 72 h post infection or by the MTS cell viability test.
EC99: compound concentration giving 2 log10 reduction in virus yield, as determined by quantifying the virus in the supernatant at 24 post infection, using an qRT-PCR based virus yield assay.25
CC50: 50% cytotoxic concentration, as determined by the MTS cell viability test. Values shown are the mean of 2–3 determinations.
MCC: minimum cytotoxic concentration, or concentration producing minimal alterations in cell morphology after 72 h incubation with compound. ND, not determined.